Pegamotecan

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NamePegamotecan
Drug Alias Name培加替康Camptothecin macrogolPolyethylene glycol camptothecinPEG-camptothecinpegamotecanum +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsStomach NeoplasmsEsophageal NeoplasmsSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEnzon Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEnzon Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsStomach NeoplasmsEsophageal NeoplasmsSarcoma

Other Information

ATC CodeN/A
Related LinksKEGG